AJP - Heart Calcium Transients and Cell-Sarcomere
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 274: H591-H599, 1998;
0363-6135/98 $5.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sherry, A. D.
Right arrow Articles by Malloy, C. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sherry, A. D.
Right arrow Articles by Malloy, C. R.
Vol. 274, Issue 2, H591-H599, February 1998

Effects of aminooxyacetate on glutamate compartmentation and TCA cycle kinetics in rat hearts

A. D. Sherry1,2, P. Zhao2, A. J. Wiethoff2, F. M. H. Jeffrey1, and C. R. Malloy1

1 Mary Nell and Ralph B. Rogers Magnetic Resonance Center, Department of Radiology, University of Texas Southwestern Medical Center, Dallas 75235-9085; and 2 Department of Chemistry, University of Texas at Dallas, Richardson, Texas 75083-0688

    ABSTRACT
Top
Abstract
Introduction
Methods
Results
Discussion
References

The nonspecific transaminase inhibitor aminooxyacetate (AOA) has multiple influences on the dynamics of 13C appearance in glutamate in rat hearts as measured by 13C nuclear magnetic resonance (NMR) without altering O2 consumption or tricarboxylic acid (TCA) cycle flux. These include the following: 1) a reduced rate of 13C enrichment at glutamate C3 and C4; 2) a near coalescence of the C3 and C4 fractional enrichment curves; 3) a dramatic alteration in the time-dependent evolution of the glutamate C4 multiplets, C4S and C4D34; and 4) a decrease in the NMR visibility of glutamate. A fit of the 13C fractional enrichment curves of glutamate C4 and C3 in the absence of inhibitor to a kinetic model of the TCA cycle gave values for transaminase flux of 7.5 µmol · min-1 · g dry wt-1 and TCA cycle flux of 7.5 µmol · min-1 · g dry wt-1, thereby confirming reports by others that the kinetics of 13C enrichment of glutamate C3 and C4 in heart tissue is significantly affected by flux through reactions other than TCA cycle. The 13C fractional enrichment data collected in the presence of 0.5 mM AOA could not be fitted using this same kinetic model. However, kinetic simulations demonstrated that the time-dependent changes in C4S and C4D34 are only consistent with a 10-fold reduction in the size of intermediate pools undergoing rapid turnover in the TCA cycle. We conclude that inhibition of glutamic-oxalacetic transaminase by AOA effectively reduces the size of the alpha -ketoglutarate pool in rapid exchange with the TCA cycle. Our data indicate that changes in glutamate multiplet areas in the 13C NMR spectra of heart (as demonstrated by glutamate C4S and C4D34) are more sensitive to alterations in metabolic pool sizes in exchange with the TCA cycle than are measurements of 13C fractional enrichment at glutamate C3 and C4.

13C fractional enrichments; tricarboxylic acid cycle flux; malate-aspartate shuttle

    INTRODUCTION
Top
Abstract
Introduction
Methods
Results
Discussion
References

CARBON-13 nuclear magnetic resonance (NMR) spectroscopy is proving to be a powerful tool for probing intermediary metabolism in intact tissues (1, 10, 13, 20, 22). Although many early studies were designed to probe linear pathways such as glycolysis or gluconeogenesis, recent emphasis has been placed on using this tool to probe metabolic pathways which reflect O2 consumption and energy production. We have shown (14) that relative flux through various metabolic pathways associated with the Krebs citric acid (tricarboxylic acid, TCA) cycle can be derived from a single 13C spectrum collected at metabolic and isotopic steady state. Numerous recent reports have shown that it is also possible to obtain dynamic 13C NMR data. In particular, rates of 13C incorporation into glutamate have been used to estimate TCA cycle flux in brain (5, 17) and heart in vivo (19) and in isolated, perfused heart preparations (3, 4, 24, 25, 27, 28). One assumption common to early dynamic NMR studies was that exchange between alpha -ketoglutarate (alpha -KG) and glutamate was rapid compared with TCA cycle flux. This assumption was supported by results reported by Chance et al. (3), who modeled 13C fractional enrichment data from extracts of hearts freeze-clamped at various times after exposure to a 13C-enriched substrate. A fit of those data to an elaborate kinetic model indicated that transaminase flux was about threefold greater than TCA cycle flux and that exchange of intermediates across the mitochondrial membrane was fast compared with other fluxes in their model. However, more recent modeling studies challenged that result and concluded that the rate or 13C appearance in glutamate in heart tissue is influenced either by exchange through the transaminases or by mitochondrial-to-cytosolic transport (4, 25, 28). These combined observations suggest that dynamic 13C NMR methods which rely on glutamate 13C fractional enrichment as a direct index of TCA cycle should be interpreted with caution, at least in the myocardium.

There is a striking disparity among published theoretical predictions of the effects of altered aminotransferase activity on the rates of 13C incorporation into glutamate C4 and C3. First, Mason et al. (17) predicted that the enrichment curves for glutamate C4 and C3 should approach one another whenever Vx/VTCA << 1, where Vx is transaminase flux and VTCA is TCA cycle flux. They presented theoretical plots for glutamate C3, showing that the rate of 13C enrichment at this carbon should increase with decreasing Vx/VTCA [results shown in Fig. 5 of Mason et al. (17) must have been calculated holding Vx constant while increasing VTCA, although this was not clearly stated]. Their prediction of more rapid appearance of 13C in glutamate C3 with decreasing Vx/VTCA was later challenged by Weiss et al. (25), who concluded that 13C flux into glutamate C3 and C4 should decrease equally with decreasing aminotransaminase flux (at constant TCA cycle flux). This theoretical prediction, along with experimental data for one group of hearts exposed to 0.1 mM aminooxyacetate (AOA), led Weiss et al. (25) to conclude that the difference in time to reach half-maximal enrichment of C4 vs. C3 (Delta t50) is insensitive to altered transaminase activity.

In this report, we have examined in detail the effects of AOA on the rates of 13C incorporation into glutamate C4 and C3 from [2-13C]acetate in isolated, perfused rat hearts and conclude that this widely used transaminase inhibitor does indeed slow 13C incorporation into both glutamate carbons [as demonstrated by Weiss et al. (25)] but also attenuates the difference between the rates of 13C enrichment at glutamate C3 and C4 [as predicted by Mason et al. (17)]. We also demonstrate that AOA alters the 13C NMR visibility of glutamate in vivo and the temporal evolution of the glutamate C4 multiplets (C4S and C4D34). These observations indicate that AOA has multiple effects on metabolism in hearts, including a net redistribution of glutamate from the cytosol to the mitochondria and a decrease in the effective size of the intermediate pools undergoing 13C isotopic turnover in the TCA cycle.

    METHODS
Top
Abstract
Introduction
Methods
Results
Discussion
References

Materials. [2-13C]acetate sodium salt (99%) was purchased from Cambridge Isotope Laboratories (Andover, MA). AOA (hemihydrochloride), Dowex 50W resin (100-200 mesh, hydrogen form), and Dowex 1-X8 resin (100-200 mesh, chloride form) were purchased from Sigma Chemical (St. Louis, MO). All other reagents from commercially available sources were of the highest quality available. Male Sprague-Dawley rats, 250-300 g, were purchased from Sasco (Houston, TX).

Heart perfusions. Rats were anesthetized in an ether atmosphere, and hearts were rapidly excised and placed in an ice-cold perfusion medium. The aorta was immediately cannulated, and hearts were perfused using standard Langendorff methods at a column height of 70 cmH2O. Typical coronary flow rates were 15-18 ml/min. A modified Krebs-Henseleit (KH) buffer containing 119.2 mM NaCl, 4.7 mM KCl, 1.25 mM CaCl2, 1.2 mM MgSO4, and 25 mM NaHCO3 was bubbled with 95% O2-5% CO2. The entire recirculation system was jacketed and maintained at 37°C. After an initial washout period of 10-15 min, hearts were perfused with 300 ml of recirculating KH buffer for 30 min before addition of 2 mM [2-13C]acetate. In the inhibitor experiments, AOA was present during this entire 30-min period to ensure equilibration of the inhibitor into all cellular compartments. After addition of [2-13C]acetate, 14 3-min proton-decoupled 13C spectra were collected during the approach to isotopic steady state (42 min). Hearts were then freeze-clamped, extracted with 3.6% cold perchloric acid, neutralized with KOH, freeze-dried, and dissolved in 0.6 ml of deuterated water (2H2O) for NMR analysis and glutamate assays.

NMR. Proton-decoupled 13C NMR spectra were obtained at 125.7 MHz on a GN-500 spectrometer. Intact heart spectra were collected in an 18-mm thin-walled NMR tube (Wilmad) with the heart bathed in perfusate, as previously described (15). The temperature of the heart was maintained at 37°C by control of the circulation perfusate temperature and by temperature control of the air surrounding the 18-mm NMR tube in the magnet using the GE VT accessory. A spherical bulb (~100 µl) containing [3-13C]propionate positioned near the heart provided an external concentration and chemical shift standard. Typically, spectra were signal averaged over periods of 3 min using a 45° observe pulse, a sweep width of ±14,000 Hz, 16K data points, and a 1-s delay between pulses and Waltz bilevel 1H decoupling.

Spectra of heart extracts were obtained in a 5-mm tube using a 45° observe pulse, 16K data points over ±14,000 Hz, and a 6-s delay between pulses. Broad-band proton decoupling was achieved using Waltz decoupling at two power levels, and the temperature was maintained at 25°C. All 13C spectra were zero filled to 32K points before Fourier transformation. The relative areas of the multiplet components in each glutamate resonance were determined by General Electric integration software and applied to a steady-state isotopomer analysis (14). 1H NMR spectra of heart extracts were obtained on the same spectrometer using a presaturation pulse sequence to eliminate residual water.

Myocardial O2 consumption and tissue assays. Myocardial O2 consumption was calculated from the difference in O2 content of perfusion medium in the supply line and coronary effluent collected from the pulmonary artery as described previously (18). Total tissue glutamate was measured fluorometrically in tissue extracts (2). Homogenized tissue samples were prepared from isolated, perfused hearts by Polytron homogenization. Glutamic-oxalacetic transaminase [GOT; aspartate aminotransferase (AST); L-aspartate:2-oxoglutarate aminotransferase; EC 2.6.1.1] activity in homogenized heart tissue samples was assayed spectrophotometrically using techniques outlined by Bergmeyer and Bernt (see Ref. 2).

Isolation of glutamate. Glutamate was isolated from rat heart extracts using two short columns, one cationic (Dowex 50W hydrogen column) and one anionic (Dowex 1-X8 formate column) to separate the strongly acidic and neutral amino acids. A column containing 6 ml of Dowex 50W in a 10-ml disposable syringe was washed with 50 ml of 2 N HCl followed by washing with distilled water (final pH of eluant was between 5 and 6). A second column containing 3 ml of Dowex 1-X8 was assembled using 0.6-cm-diameter glass Pasteur pipette. This column was washed with 20 ml of 2 M formic acid followed by 20 ml of distilled water (final pH of eluant was near 7). Neutralized heart extract samples were dissolved in 2 ml of distilled water at pH 2.5-3.0 (adjusted by HCl) and applied to the Dowex 50W column. The column was washed with 25 ml of distilled water to remove carboxylic acids followed by 30 ml of 2 M NH4OH to recover all amino acids. The amino acid fraction was freeze dried and redissolved into 2 ml of distilled water, and the pH was adjusted to 8 using KOH. This fraction was applied to the Dowex 1-X8 column and washed with 200 ml of distilled water to remove neutral amino acids and glycerol. Glutamate was eluted with 10 ml of 0.5 M formic acid, freeze dried to remove excess formic acid, and redissolved into 0.5 ml 2H2O for 1H NMR analysis.

Modeling. A kinetic model similar to that of Chance et al. (3) was constructed. Single pools of citrate, alpha -KG, succinate, malate, oxalacetate, and glutamate were included in reactions that involved the Krebs TCA cycle, exchange between alpha -KG and glutamate, and anaplerosis. Differential equations describing the time-dependent changes in concentration of the individual 13C isotopomers in each metabolite pool were solved numerically. This kinetic model was used to fit the 13C fractional enrichment curves of glutamate C4 and C3 to optimal values of Vx and VTCA (where Vx is transaminase flux, mitochondrial export flux, or some combination thereof and VTCA is TCA cycle flux) and to simulate time-dependent changes in the glutamate spectrum (both C3 and C4 fractional enrichments and C4 multiplet areas) as a function of Vx/VTCA and total TCA cycle intermediate pool size.

Statistical analysis. All results are reported as means ± SD. The Student's t-test was used to compare means; P < 0.05 was considered significant.

    RESULTS
Top
Abstract
Introduction
Methods
Results
Discussion
References

Rates of 13C enrichment in glutamate with or without AOA. Temporal changes in proton-decoupled 13C NMR spectra of isolated, perfused rat hearts in the absence and presence of 0.5 mM AOA are compared in Fig. 1. The average glutamate C3 and C4 resonance areas for five or six hearts in each group are shown plotted vs. time in Fig. 2. There are three obvious differences between these data: first, 13C enrichment of glutamate C4 and C3 occurred more slowly in the heart perfused with the transaminase inhibitor; second, there was less glutamate detected by 13C NMR at steady state in the hearts perfused with AOA (intensities of glutamate resonances in these plots were standardized relative to an external [3-13C]propionate reference at 11 ppm); and third, the difference in rates of 13C incorporation into glutamate C4 and C3 was much less in the presence of inhibitor. Homogenized tissue from hearts perfused with 0.5 mM AOA had 60% less GOT activity than control hearts (in vitro assays), whereas coronary flow, heart rate, developed pressure, and O2 consumption (in vivo assays) were unaffected by the presence of the inhibitor (see Table 1).


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 1.   Dynamic 13C nuclear magnetic resonance (NMR) spectra of rat hearts perfused with 2 mM [2-13C]acetate with (A) and without (B) 0.5 mM aminooxyacetate (AOA). These expanded spectra show only glutamate C4 (~34.5 ppm) and C3 (~28 ppm) resonances.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 2.   A summary of average glutamate C4 (top curve, A and B) and C3 (bottom curve, A and B) resonance areas from hearts perfused as described in Fig. 1 either with (A) or without (B) 0.5 mM AOA (n = 5 in each group). Resonance areas were normalized using signal from [3-13C]propionate contained in an external reference bulb. Solid curves represent a fitting of data to a kinetic model described in text.

                              
View this table:
[in this window]
[in a new window]
 
Table 1.   In vitro transaminase activity and physiological parameters for hearts perfused with 2 mM [2-13C]acetate

In separate experiments, hearts were perfused with even higher concentrations of AOA to determine whether the kinetics and steady-state levels of 13C-enriched glutamate could be further depressed. Heart function (as detected by rate-pressure product) was not significantly different in groups perfused with 0, 0.5, 1, or 2 mM AOA. The rates of glutamate enrichment with 13C did appear to slow even further with increasing concentrations of AOA (spectra not shown), but less 13C-enriched glutamate was also detected by NMR at the higher inhibitor concentrations, and this precluded an accurate assessment of 13C resonances areas.

13C NMR spectra of intact hearts at steady state. Figure 3B compares glutamate signal intensities in three different intact hearts after perfusion to steady state with [2-13C]acetate and 0.5, 1, or 2 mM AOA. Although the amount of 13C-enriched glutamate in these three hearts appeared to be lower at the high levels of AOA, slight variations in heart size could have contributed to these differences. Thus we also compared glutamate intensities from a single heart, before and after exposure to AOA. The stacked plot shown in Fig. 3A compares the glutamate resonance intensities in a heart first perfused to steady state with [2-13C]acetate and then every 3 min after addition of 0.5 mM AOA (with [2-13C]acetate still present). The temporal intensity changes detected in all three glutamate resonances after addition of AOA showed quite clearly that less glutamate was detected by 13C NMR when the inhibitor was present.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 3.   A: set of 13C NMR spectra of glutamate from a single heart perfused to steady state with [2-13C]acetate before addition of AOA (front spectrum in stack) and every 5 min after addition of 0.5 mM AOA. B: 13C NMR spectra of glutamate in separate hearts perfused to steady state with [2-13C]acetate and 0.5, 1.0, or 2.0 mM AOA.

13C NMR spectra of extracts of tissue at isotopic steady state. The observations described above from intact, perfused hearts suggested that either 1) less [2-13C]acetate entered the TCA cycle as [2-13C]acetyl-CoA when the transaminase inhibitor was present, 2) addition of inhibitor resulted in a decrease in total tissue glutamate, or 3) glutamate was sequestered in some cellular compartment in intact hearts perfused with AOA that rendered it at least partially invisible by 13C NMR. High-resolution 13C spectra of extracts of hearts perfused to steady state with or without AOA were not significantly different (not shown). A steady-state isotopomer analysis (14) of those spectra indicated that the fraction of acetyl-CoA derived from [2-13C]acetate (FC2) and relative anaplerosis (y) was identical in the presence and absence of inhibitor (Table 2). Total tissue glutamate (as measured enzymatically and from 13C NMR spectra of extracts) was also independent of inhibitor. 1H NMR spectra of isolated, purified glutamate from these tissues provided an independent measure of the 13C fractional enrichment glutamate C4. Those values, reported in the last column of Table 2, were significantly less than FC2 as measured by 13C NMR. This indicated that there was a small pool of glutamate in these hearts (~20% of total glutamate) that was not in exchange with TCA cycle intermediates and that the size of this nonexchanging pool was not affected by the presence of AOA (Table 2).

                              
View this table:
[in this window]
[in a new window]
 
Table 2.   Total tissue glutamate, fraction of acetyl-CoA derived from [2-13C]acetate, relative anaplerosis, and fractional 13C enrichment of glutamate C4

Time-dependent evolution of glutamate multiplets. 13C NMR spectra such as those shown in Fig. 1 had sufficiently good signal-to-noise to allow deconvolution of the singlet (S) and doublet (D34) components of glutamate C4. These data, shown in Fig. 4, indicate there was a dramatic difference in the temporal evolution of C4S and C4D34 (and other glutamate resonance multiplets as well; not shown) in hearts perfused with or without AOA. Although C4S was high and C4D34 low in the first 3-min spectrum of hearts in the absence of AOA, C4D34 was already higher than C4S in the first 3-min spectrum of hearts exposed to AOA. This was confirmed in extracts of hearts freeze-clamped at 5 min after addition of [2-13C]acetate with and without AOA. The glutamate C4 resonance from two representative spectra are shown in Fig. 5. The average C4D34/C4S from four such experiments was 0.64 ± 0.11 in hearts without AOA and 1.30 ± 0.12 in hearts with AOA. Because O2 consumption and hence TCA cycle flux were identical in the two groups of hearts, the larger C4D34/C4S and the faster enrichment of glutamate C3 (relative to C4, see Fig. 2) in the AOA group suggested that the size of the TCA cycle intermediate pools in exchange with glutamate was smaller in hearts exposed to AOA than in control hearts. This was confirmed by 1H spectroscopy of these same samples (Fig. 5). The larger 13C satellite wings around the glutamate H4 resonance centered at 2.34 ppm verified that a larger fraction of total tissue glutamate had exchanged with alpha -KG in hearts without AOA. The average C4F at 5 min was 0.65 ± 0.05 in hearts without AOA vs. 0.22 ± 0.01 in hearts with AOA (n = 4 for each group). This confirmed that the kinetics of exchange among TCA cycle intermediate pools were different in the two experiments even though glutamate reached the same level of 13C fractional enrichment and isotopomeric composition after a period of 40-50 min in both groups of hearts (compare FC2 values for 2 groups at steady state; Table 2).


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 4.   Glutamate C4 resonance multiplet areas obtained with resolution enhancement and deconvolution of spectra such as those shown in Fig. 1. C4S represents singlet component and C4D34 represents doublet component, each expressed as a fraction of total C4 resonance area. Data in B are from hearts perfused without inhibitor, whereas those in A are from hearts perfused with 0.5 mM AOA (n = 5 in each group).


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 5.   13C and 1H NMR spectra (left and right, respectively) of extracts of hearts freeze-clamped after 5 min of exposure to 2 mM [2-13C]acetate (0.5 mM AOA). These hearts were first perfused with unlabeled acetate with (top) or without AOA (bottom) for 30 min and then perfused with [2-13C]acetate with or without AOA for 5 min before freeze clamping.

    DISCUSSION
Top
Abstract
Introduction
Methods
Results
Discussion
References

Dynamic NMR measurements of 13C enrichment in glutamate C3 and C4 offer considerable potential for estimating TCA cycle flux in vivo; yet the assumptions involved in such measurements and their validity have generated considerable scientific debate. The first concern is whether the rate of 13C appearance in glutamate is limited to any significant extent by an exchange [alpha -KGleft-right-arrow glutamate (Glu)] or transport (Mitoleft-right-arrow Cyto) process. In an early kinetic study using 13C fractional enrichment data derived from spectra of tissue extracts, Chance et al. (3) estimated that exchange between alpha -KG and glutamate was about threefold faster than TCA cycle flux in hearts perfused with acetate. They concluded that the rate of exchange between cytosolic and mitochondrial metabolite pools was fast relative to other fluxes and that the size of each metabolite pool in exchange in the cycle was equal to that measured enzymatically in tissue extracts. A few years later, the first in vivo NMR demonstration of 13C kinetics to measure TCA cycle flux was elegantly demonstrated by Fitzpatrick et al. (5). They fitted the 13C enrichment curves of glutamate C4 and C3 in rat brain obtained by 1H observe-13C edited spectroscopy to a kinetic model that also assumed that the entire cerebral glutamate pool was in rapid exchange with alpha -KG. This gave a reasonable 1.4 µmol · g-1 · min-1 value for TCA cycle flux, in agreement with values determined using other techniques. This kinetic model was later extensively validated (16, 17) and applied to 13C NMR data collected from human brain during infusion of [1-13C]glucose (6). It was concluded that exchange between alpha -KG and glutamate (Vx) was 72 times faster than VTCA in human brain (16).

More recent 13C NMR kinetic investigations on isolated, perfused hearts have reported that the rates at which 13C appears in glutamate C3 and C4 may be influenced by processes other than TCA cycle flux (4, 28). Chatham et al. (4) followed 13C incorporation into glutamate C3 and C4 in isolated rat hearts perfused with [2-13C]acetate and fitted those data using a similar kinetic model as described earlier by Chance et al. (3). However, they found that alpha -KGleft-right-arrow Glu exchange was 18% that of TCA cycle flux, a result quite different from the earlier Chance et al. report, in which the data were derived from spectra of tissue extracts. Somewhat later, Yu et al. (28) applied a mathematically simplified kinetic model to 13C fractional enrichment data from intact rabbit hearts perfused with [2-13C]acetate and reported that two rate-limiting processes, TCA cycle flux (i.e., VTCA) and alpha -KGleft-right-arrow Glu exchange (F1), contribute nearly equally to the glutamate enrichment kinetics. A comparison of their kinetically determined F1 flux variable with estimates of total cytosolic transaminase flux (GOTCyto) from in vitro assays led them to conclude that flux through GOTCyto was much too high to contribute to the NMR observables, and thus F1 probably reflects some transport process, perhaps transport of alpha -KG from the mitochondria to the cytosol. No attempt was made to estimate mitochondrial transaminase flux (GOTMito) in that study probably due to the uncertainties in the distribution of alpha -KG, glutamate, aspartate, and oxalacetate among the cytosolic and mitochondrial compartments. Finally, Weiss et al. (25), using a kinetic model similar to that used by Chance et al. (3) and Chatham et al. (4), reported that alpha -KGleft-right-arrow Glu exchange via transamination was nearly equal to TCA cycle flux in isovolumic, paced rat hearts perfused with [2-13C]acetate. In each of these studies, total tissue glutamate, as measured enzymatically (3, 28) or as detected by 13C NMR (4, 25), was used to fit the kinetic data. Thus four independent 13C kinetic modeling studies of hearts perfused with [2-13C]acetate have yielded somewhat disparate results. Chance et al. (3) concluded that flux through the transaminases was a factor of 3 larger than TCA cycle flux, Chatham et al. (4) concluded that transaminase flux (as part of malate-aspartate shuttle) was smaller than TCA cycle flux, and Weiss et al. (25) concluded that transaminase flux and TCA cycle flux were comparable, whereas Yu et al. (28), on the basis of direct experimental evidence for high GOTCyto flux, suggested that flux of alpha -KG from the mitochondria to the cytosol (but not transaminase flux) was comparable to TCA cycle flux.

A kinetic model (Jeffrey, unpublished results) similar to that of Chance et al. (3) was used to fit the 13C fractional enrichment data of Fig. 2 to obtain best values of Vx (flux through an undefined process involving interchange of alpha -KG and glutamate carbons) and VTCA for both groups of hearts (AOA). The solid lines drawn through the data of Fig. 2 represent the best fit of the data to a model that fixed FC2 at 0.93, y at 0.05, total tissue glutamate at 22 µmol/g dry wt, and the remaining TCA cycle intermediates at values reported by Chance et al. (3) for acetate-perfused hearts. The fit of the data in the absence of inhibitor gave Vx = 7.5 µmol · min-1 · g dry wt-1 and VTCA = 7.5 µmol · min-1 · g dry wt-1, quite similar to the values reported by Yu et al. (28) for acetate-perfused rabbit hearts. Although our fitted value of VTCA was somewhat lower than that predicted by our O2 consumption measurements (expected value was 19/2 = 9.5 µmol · min-1 · g dry wt-1), the agreement is reasonable considering the assumptions involving the sizes of the all TCA cycle intermediate pools. Importantly, our data in the absence of inhibitor indicate that Vx approx  VTCA, in agreement with Weiss et al. (Vx/VTCA = 0.86; Ref. 25) and Yu et al. (Vx/VTCA = 0.92; Ref. 28) but clearly different from the conclusions reached by Chance et al. (Vx/VTCA = 2.8; Ref. 3) and Chatham et al. (Vx/VTCA = 0.18; Ref. 4).

Effects of AOA on pre-steady-state 13C enrichment of glutamate C3 and C4. We have shown in this study that an inhibition of total cellular transaminase activity by 60% (as measured in vitro) has a dramatic effect on the rates of 13C appearance in glutamate C3 and C4. Inasmuch as flux through GOTCyto has been estimated at 20 times greater than TCA cycle flux in isolated rabbit hearts perfused with acetate (28), how can AOA at these levels have such a dramatic effect on the rates of 13C enrichment at glutamate C3 and C4? If GOTCyto flux is indeed much greater than TCA cycle flux in the rat heart, then one must consider a possible role of GOTMito in this process. Using the kinetic parameters for GOTMito and metabolite concentrations reported by Yu et al. (28) and making the assumption that 20% of total tissue aspartate and alpha -KG is mitochondrial and 10% of total tissue water is mitochondrial, one can arrive at an estimate of 90 µmol · min-1 · g dry wt-1 for GOTMito flux. Clearly, this estimate may suffer from the likely oversimplifying assumption that the kinetic parameters of GOTMito in situ are the same as those measured in vitro (28). Nevertheless, the calculation suggests that neither GOTCyto nor GOTMito may limit the rate of 13C appearance in glutamate C3 and C4 in the absence of inhibitor. If one further assumes that AOA does nothing more than inhibit both GOTCyto and GOTMito by 60%, then we should not have detected the dramatic changes in the rate of 13C appearance in glutamate C3 and C4 shown in Fig. 2. This suggests that AOA must be affecting other metabolic processes in addition to partial inhibition of the transaminases. This conclusion was supported in our attempts to fit the 13C fractional enrichment data for hearts perfused with 0.5 mM AOA (Fig. 2A) using the same kinetic model as described above. The solid lines through the inhibitor data of Fig. 2 show the best fit using the same assumptions as stated above plus VTCA fixed at 7.5 µmol · min-1 · g dry wt-1. Although Vx tended to decrease in all calculations (curves shown are for a value of 5.8 µmol · min-1 · g dry wt-1), the poor agreement between experimental and calculated data indicates that this kinetic model is too simplistic. Again, the near coincidence of the C4 and C3 enrichment curves indicates that much smaller pool(s) of intermediates were in rapid exchange with the TCA cycle reactions in this group of hearts (see modeling results below).

Weiss et al. (25) also examined the effects of AOA (at a 5-fold lower concentration) on the 13C enrichment curves of glutamate but did not observe coalescence of the C4 and C3 enrichment curves or a change in the total amount of glutamate detected by 13C NMR. Interestingly, they reported that 0.1 mM AOA inhibited 90-95% of the total aspartate aminotransferase activity in heart tissue (as assayed in vitro); yet a fit of their 13C NMR dynamic data to their kinetic model indicated that transaminase flux was reduced by only 50% in vivo (25). Although Weiss et al. ascribed this to differences between in vitro and in vivo enzyme kinetics, the rather substantial differences between their results and ours indicate that the same level of inhibition may not have been achieved in the two experiments. The data presented here indicate that the empirical method advocated by Weiss et al. (24), which uses the Delta t50 for C4 vs. C3 as an index of TCA cycle flux, cannot always be used with confidence, even if a change in 13C NMR-detected metabolite levels is considered. For example, in our experiments, Delta t50 was very small in the presence of 0.5 mM AOA, and yet O2 consumption (hence TCA cycle flux) was unchanged.

Evolution of glutamate multiplets with time. We also demonstrated for the first time that the evolution of glutamate 13C isotopomers, as reported by time-dependent evolution of C4S and C4D34, provides additional kinetic evidence about exchanging pools that is not easily detected in 13C fractional enrichment measurements. To illustrate this point, we have used our kinetic model to simulate the changes expected in the shape of the 13C enrichment curves of glutamate C4 and C3 as alpha -KGleft-right-arrow Glu exchange (Vx) is reduced at a fixed VTCA. Figure 6 shows the resulting simulations at two intermediate pool sizes (differing by a factor of 10) and for values of Vx/VTCA = 2 and 0.1, with VTCA held constant. As originally predicted Mason et al. (17) and demonstrated here experimentally, the simulation shows that the intensities of glutamate C3 and C4 should approach one another as Vx <<  VTCA. This is quite intuitive. By slowing communication (exchange) between a relatively small pool of TCA cycle intermediates and the relatively large glutamate pool, we have effectively increased the rate at which 13C reaches the C3 position relative to C4 without increasing VTCA. A comparison of Fig. 6, left and right, indicates that the shapes of the C3 and C4 kinetic curve are relatively insensitive to the size of the TCA cycle intermediate pool undergoing rapid 13C turnover, both for Vx/VTCA = 2 (simulating our control hearts) and for Vx/VTCA = 0.1 (simulating hearts inhibited by AOA). This same conclusion was also reached by Chatham et al. (4) and Yu et al. (28) for control hearts. Because the curves shown in Fig. 6A for both sets of conditions did not change as the total TCA cycle intermediate pool size was decreased by a factor of 10, we must conclude that it is not possible to judge the size of the exchanging pools based upon C4 and C3 fractional enrichment data alone. However, this situation is quite different for the glutamate multiplets. Figure 6, bottom, illustrates that the glutamate C4 multiplet, C4D34, is quite sensitive to both Vx/VTCA and intermediate pool sizes. In particular, C4D34 reaches its maximum much more rapidly when Vx/VTCA and the combined size of the TCA cycle intermediate pools are both small.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 6.   Predicted effects of changing total tricarboxylic acid (TCA) cycle intermediate pool size (A vs. B) and alpha -ketoglutarate (alpha -KG)left-right-arrow glutamate (Glu) flux (Vx) on fractional 13C enrichment of glutamate C4 and C3 (top) and evolution of glutamate C4 doublet (C4D34; bottom) vs. time using a kinetic model similar to that described by Chance et al. (3). VTCA was held constant in all calculations. Vx/VTCA was fixed at 2 (solid lines) or 0.1 (dashed lines). Total tissue glutamate was fixed at 20 µmol/g dry wt in all calculations, and all remaining exchanging TCA cycle intermediate pool sizes were either set equal to those reported by Chance et al. (3) (data shown on A) or uniformly decreased by a factor of 10 (data shown on B).

The experimental data of Fig. 4 show that C4D34 is small early during isotopic enrichment of glutamate in the absence of AOA and the shape of its temporal evolution is similar to the solid curves shown in Fig. 6, bottom, for Vx/VTCA = 2. Experiments performed in the presence of inhibitor, however, show that C4D34 is significantly larger not only during early glutamate turnover but throughout its approach to isotopic steady state (Fig. 4). This could only be simulated by allowing the total size of the TCA intermediate pools in exchange within the cycle to decrease significantly (dotted line in Fig. 6B, bottom). Thus AOA appears to not only decrease Vx but also the size of intermediate pools undergoing 13C turnover in the cycle. Although the simulation did not reproduce some of the finer experimental details (in particular, experimental C4D34 and C4S values were relatively constant during early turnover and then gradually changed between 20 and 40 min), it does illustrate that C4D34 can quickly rise above C4S when TCA cycle intermediate pools are small and exchange into the much larger glutamate pool is slow compared with TCA cycle flux. Thus the standard assumption that the size of the intermediate pools in exchange in the cycle is equal to the total metabolite pools measured in extracts may not always be valid and any kinetic model based on that assumption should be used with the present observations in mind.

NMR visibility of glutamate. This study has shown that the NMR visibility of glutamate can be altered by a common metabolic inhibitor, without changing total tissue glutamate, heart rate, developed pressure, or O2 consumption. Safer et al. (21) have also reported that 0.4 mM AOA does not markedly affect O2 consumption by hearts but does alter the cytosolic-mitochondrial distribution of several metabolites associated with the malate-aspartate shuttle. It has been shown by Safer et al. in heart (21) and Kauppinen et al. in brain (7) that AOA at these levels increases the ratio of cytosolic NADH/NAD+, which in turn increases cytosolic malate and decreases cytosolic aspartate. This would in turn induce aspartate efflux from mitochondria and glutamate influx into mitochondria (21), perhaps leading to a net redistribution of glutamate toward the mitochondrial compartment at equilibrium. Our observation that the 13C-enriched glutamate signal decreases by ~30% in hearts perfused with AOA is entirely consistent with these prior metabolic observations. This is important because kinetic models generally assume that all glutamate in exchange with the TCA cycle is NMR visible and that it equals total tissue glutamate as measured in extracts. In most cases, this appears to be a reasonable assumption (4, 16, 17, 24, 28), but our study demonstrates that there may be metabolic situations in which glutamate can become partially NMR invisible, perhaps by redistributing among subcellular compartments.

Summary. Dynamic 13C NMR studies of hearts perfused with [2-13C]acetate with or without the transaminase inhibitor, AOA, have shown that this inhibitor has multiple effects on metabolism in the heart. We have shown that as little as 0.5 mM AOA inhibits total transaminase activity by 60% and effectively slows communication between the mitochondrial and cytosolic spaces of the myocardium without altering TCA cycle flux. One unanticipated finding was that AOA also altered the amount of glutamate detected by NMR. The NMR data (both extract spectra and in vivo spectra) indicate that a small exchanging pool of metabolites turns over quite rapidly in the presence of inhibitor. This small, presumably mitochondrial, pool then exchanges with mitochondrial and cytosolic glutamate (GluMito and GluCyto, respectively) at rates determined by residual transaminase activity and transport processes. This was reflected in an unusually high C3/C4 and unusally large C4D34 early during cycle turnover. The sizes of GluMito and GluCyto cannot be firmly established by our experimental data nor can we determine whether multiple subcompartmental pools exist within the cytosolic and mitochondrial spaces. GluMito has been reported to be as high as 30% (26) and as low as 10% (8) of total tissue glutamate in normoxic hearts; so if our NMR observations in the presence of AOA indeed reflect a redistribution of ~20% of GluCyto to GluMito, most of the total tissue glutamate would still remain in the cytosol. Given that the spin-lattice relaxation times and nuclear Overhauser enhancements of 13C-enriched glutamate in hearts perfused with [2-13C]acetate are nearly identical to those measured in aqueous saline at the same temperature (22), we assume that all glutamate detected by 13C NMR in vivo is GluCyto and that GluMito could be either invisible or less visible due to slower diffusion of molecules in the highly viscous mitochondrial matrix (23). Furthermore, our observation that ~20% of total cellular glutamate is totally sequestered and never becomes enriched with 13C in acetate-perfused hearts (in agreement with previous reports; Refs. 11, 12) illustrates that multiple glutamate pools can indeed exist in hearts, so that dividing total glutamate into further "kinetic" subcellular compartments may not be totally unreasonable.

    ACKNOWLEDGEMENTS

This study was supported by a Clinical Investigator and Merit Review Award of the Department of Veterans Affairs and by National Institutes of Health Grants P41-RR-02584 and HL-34557.

    FOOTNOTES

Address for reprint requests: A. D. Sherry, Dept. of Chemistry, University of Texas at Dallas, PO Box 830688, Richardson, TX 75083-0688.

Received 24 January 1997; accepted in final form 17 October 1997.

    REFERENCES
Top
Abstract
Introduction
Methods
Results
Discussion
References

1.   Beckmann, N. In vivo 13C spectroscopy in humans. In: In Vivo MR Spectroscopy: Potential and Limitations, edited by P. Diehl, E. Fluck, H. Gunther, R. Kosfeld, and J. Seelig. New York: Springer-Verlag, 1992, vol. 28, p. 73-100.

2.   Bergmeyer, H. U. Methods of Enzymatic Analysis. New York: Academic, 1974, vols. 2 (p. 727-733) and 4 (p. 1704-1708).

3.   Chance, E. M., H. Seeholzer, K. Kobayashi, and J. R. Williamson. Mathematical analysis of isotope labeling in the citric acid cycle with applications to 13C NMR studies in perfused rat hearts. J. Biol. Chem. 258: 13785-13794, 1983[Abstract/Free Full Text].

4.   Chatham, J. C., J. R. Forder, J. D. Glickson, and E. M. Chance. Calculation of absolute metabolic flux and the elucidation of the pathways of glutamate labeling in perfused rat heart by 13C NMR spectroscopy and nonlinear least squares analysis. J. Biol. Chem. 270: 7999-8008, 1995[Abstract/Free Full Text].

5.   Fitzpatrick, S. M., H. P. Hetherington, K. L. Behar, and R. G. Shulman. The flux from glucose to glutamate in the rat brain in vivo as determined by 1H observe, 13C edited NMR spectroscopy. J. Cereb. Blood Flow Metab. 10: 170-179, 1990[Medline].

6.   Gruetter, R., E. J. Novotny, S. D. Boulware, G. F. Mason, D. L. Rothman, G. I. Shulman, J. W. Prichard, and R. G. Shulman. Localized 13C NMR spectroscopy in the human brain of amino acid labeling from D-[1-13C]glucose. J. Neurochem. 63: 1377-1385, 1994[Medline].

7.   Kauppinen, R. A., T. S. Sihra, and D. G. Nicholls. Aminooxyacetic acid inhibits the malate-aspartate shuttle in isolated nerve terminals and prevents the mitochondria from using glycolytic substrates. Biochim. Biophys. Acta 930: 173-178, 1987[Medline].

8.   LaNoue, K. F., W. J. Nicklas, and J. R. Williamson. Control of citric acid cycle activity in rat heart mitochondria. J. Biol. Chem. 245: 102-111, 1970[Abstract/Free Full Text].

9.   LaNoue, K. F., and M. E. Tischler. Electrogenic characteristics of the mitochondrial glutamate-aspartate antiporter. J. Biol. Chem. 249: 7522-7528, 1974[Abstract/Free Full Text].

10.   Laughlin, M. R., J. Taylor, A. S. Chesnick, M. Degroot, and R. S. Balaban. Pyruvate and lactate metabolism in the in vivo dog heart. Am. J. Physiol. 264 (Heart Circ. Physiol. 33): H2068-H2079, 1993[Abstract/Free Full Text].

11.   Lewandowski, E. D. Nuclear magnetic resonance evaluation of metabolic and respiratory support of work load in intact rabbit hearts. Circ. Res. 70: 576-582, 1992[Abstract/Free Full Text].

12.   Lewandowski, E. D., and C. Hulbert. Dynamic changes in 13C NMR spectra of intact hearts under conditions of varied metabolite enrichment. Magn. Reson. Med. 19: 186-190, 1991[Medline].

13.   London, R. E. 13C labeling studies of metabolic regulation. Prog. NMR Spectrosc. 20: 337-383, 1988.

14.   Malloy, C. R., A. D. Sherry, and F. M. H. Jeffrey. Analysis of tricarboxylic acid cycle of the heart using 13C NMR spectroscopy. Am. J. Physiol. 259 (Heart Circ. Physiol. 28): H987-H995, 1990[Abstract/Free Full Text].

15.   Malloy, C. R., J. R. Thompson, F. M. H. Jeffrey, and A. D. Sherry. Contribution of exogenous substrates to acetyl coenzyme A: measurement by 13C NMR under nonsteady-state conditions. Biochemistry 29: 6756-6761, 1990[Medline].

16.   Mason, G. F., R. Gruetter, D. L. Rothman, K. L. Behar, R. G. Shulman, and E. J. Novotny. Simultaneous determination of the rates of the TCA cycle, glucose utilization, alpha -ketoglutarate/glutamate exchange, and glutamine synthesis in human brain by NMR. J. Cereb. Blood Flow Metab. 15: 12-25, 1995[Medline].

17.   Mason, G. F., D. L. Rothman, K. L. Behar, and R. G. Shulman. NMR determination of the TCA cycle rate and alpha -ketoglutarate/glutamate exchange rate in rat brain. J. Cereb. Blood Flow Metab. 12: 434-447, 1992[Medline].

18.   Neely, J., H. Liebermeister, E. Battersby, and H. Morgan. Effect of pressure development on oxygen consumption by isolated rat hearts. Am. J. Physiol. 212: 804-814, 1967.

19.   Robitaille, P.-M. L., D. P. Rath, T. E. Skinner, A. M. Abduljalil, and R. L. Hamlin. Transaminase reaction rates, transport activities and TCA cycle analysis by post-steady state 13C NMR. Magn. Reson. Med. 30: 262-266, 1993[Medline].

20.   Rothman, D. L., I. Magnusson, L. D. Katz, R. G. Shulman, and G. I. Shulman. Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR. Science 254: 573-576, 1991[Abstract/Free Full Text].

21.   Safer, B., C. M. Smith, and J. R. Williamson. Control of the transport of reducing equivalents across the mitochondrial membrane in perfused rat heart. J. Mol. Cell. Cardiol. 2: 111-124, 1971[Medline].

22.   Sherry, A. D., and C. R. Malloy. Cardiac metabolism. In: NMR in Physiology and Biomedicine, edited by R. J. Gillies. San Diego, CA: Academic, 1994, p. 439-449.

23.   Srere, P. A. The structure of the mitochondrial membrane-matrix component. Trends Biochem. Sci. 7: 373-378, 1982.

24.   Weiss, R. G., S. T. Gloth, R. Kalil-Filho, V. P. Chacko, M. D. Stern, and G. Gerstenblith. Indexing tricarboxylic acid cycle flux in intact hearts by carbon-13 nuclear magnetic resonance. Circ. Res. 70: 392-408, 1992[Abstract/Free Full Text].

25.   Weiss, R. G., M. D. Stern, C. P. De Albuquerque, K. Vandegaer, V. P. Chacko, and G. Gerstenblith. Consequences of altered aspartate aminotransferase activity on 13C-glutamate labelling by the tricarboxylic acid cycle in intact rat hearts. Biochim. Biophys. Acta 1243: 543-548, 1995[Medline].

26.   Wiesner, R. J., U. Kreutzer, P. Rosen, and M. K. Grieshaber. Subcellular distribution of malate-aspartate cycle intermediates during normoxia and anoxia in the heart. Biochim. Biophys. Acta 936: 114-123, 1988[Medline].

27.   Yu, X., L. T. White, N. M. Alpert, and E. D. Lewandowski. Subcellular metabolite transport and carbon isotope kinetics in the intramyocardial glutamate pool. Biochemistry 35: 6963-6968, 1996[Medline].

28.   Yu, X., L. T. White, C. Doumen, L. A. Damico, K. F. Lanoue, N. M. Alpert, and E. D. Lewandowski. Kinetic analysis of dynamic 13C NMR spectra: metabolic flux, regulation, and compartmentation in hearts. Biophys. J. 69: 2090-2102, 1995[Abstract/Free Full Text].


AJP Heart Circ Physiol 274(2):H591-H599
0363-6135/98 $5.00 Copyright © 1998 the American Physiological Society



This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. A. Carvalho, T. B. Rodrigues, P. Zhao, F. M. H. Jeffrey, C. R. Malloy, and A. D. Sherry
A 13C isotopomer kinetic analysis of cardiac metabolism: influence of altered cytosolic redox and [Ca2+]o
Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H889 - H895.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. L. Garcia-Martin, M. A. Garcia-Espinosa, P. Ballesteros, M. Bruix, and S. Cerdan
Hydrogen Turnover and Subcellular Compartmentation of Hepatic [2-13C]Glutamate and [3-13C]Aspartate as Detected by 13C NMR
J. Biol. Chem., March 1, 2002; 277(10): 7799 - 7807.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. A. Carvalho, P. Zhao, C. B. Wiegers, F. M. H. Jeffrey, C. R. Malloy, and A. D. Sherry
TCA cycle kinetics in the rat heart by analysis of 13C isotopomers using indirect 1H[13C] detection
Am J Physiol Heart Circ Physiol, September 1, 2001; 281(3): H1413 - H1421.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
R. Gruetter, E. R. Seaquist, and K. Ugurbil
A mathematical model of compartmentalized neurotransmitter metabolism in the human brain
Am J Physiol Endocrinol Metab, July 1, 2001; 281(1): E100 - E112.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
F. M. H. Jeffrey, A. Reshetov, C. J. Storey, R. A. Carvalho, A. D. Sherry, and C. R. Malloy
Use of a single 13C NMR resonance of glutamate for measuring oxygen consumption in tissue
Am J Physiol Endocrinol Metab, December 1, 1999; 277(6): E1111 - E1121.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sherry, A. D.
Right arrow Articles by Malloy, C. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sherry, A. D.
Right arrow Articles by Malloy, C. R.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online